Background: The socioeconomic burdens of osteoporosis and related fractures have increased in parallel with population aging. The Korea Society of Bone and Mineral Research published fact sheets on these topics in 2017, 2018, and 2019. This study provides complied epidemiological data based on these fact sheets for understanding current status of osteoporosis in Korea.
Methods: Data from the Korea National Health and Nutrition Examination Survey (2008-2011) performed by the Korea Centers for Disease Control and Prevention and from National Health Information database (2008-2016) by National Health Insurance Service of Korea was used for analyzing the prevalence and incidence of osteoporosis and related fractures, respectively, fatality rates after fractures, and prescription status of anti-osteoporotic medications (AOMs).
Results: Among Korean adults aged ≥50 years, 22.4% and 47.9% had osteopenia or osteoporosis, respectively. Incidences of osteoporotic hip, vertebral, humerus, and distal radius fractures plateaued in 2013. The cumulative incidence of subsequent fractures gradually increased over 4 years of follow-up once an osteoporotic fracture occurred. Crude fatality rates in the first 12 months after hip fracture were 14.0% for women and 21.0% for men. Only 33.5% of patients with osteoporosis took AOMs, and even after an osteoporotic fracture, only 41.9% of patients took AOMs within the following 12 months. Despite a steady increase in AOM prescriptions of ~6% per annum, only 33.2% of patients were medication compliant (medication possession ratio ≥80%) at 12 months after treatment initiation.
Conclusions: Continuous efforts are required to diagnose patients at high risk of fracture and ensure proper management in Korea.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746478 | PMC |
| http://dx.doi.org/10.11005/jbm.2020.27.4.281 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associations between bone material strength index and FRAX scores.
J Bone Miner Metab
January 2025
Deakin University, IMPACT- Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Geelong, Australia.
Introduction: Impact microindentation (IMI) measures bone material strength index (BMSi) in vivo. However, its ability to predict fractures is still uncertain. This study aimed to determine the association between BMSi and 10 year fracture probability, as calculated by the FRAX algorithm.
View Article and Find Full Text PDFCardiovascular safety of osteoanabolic agents.
J Bone Miner Metab
January 2025
Toranomon Hospital Endocrine Center, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan.
Purpose: Several osteoanabolic agents have been developed to build new bone more efficiently than anti-resorptive drugs. Among them, romosozumab, an anti-sclerostin antibody, is a potent pharmacological tool to prevent fractures in osteoporosis patients. The efficacy of romosozumab in preventing osteoporotic fractures is robust.
View Article and Find Full Text PDFUnilateral and bilateral PVP for thoracolumbar OVCF with distant lumbosacral pain: a single-center retrospective analysis.
World Neurosurg
January 2025
Department of Orthopaedics, General Hospital of Northern Theatre Command, Shenyang 110016. Electronic address:
Backgrounds: Previous studies have found that percutaneous vertebroplasty (PVP) can effectively improve the local pain of the affected vertebra caused by thoracolumbar osteoporotic vertebral compression fracture (OVCF) regardless of unilateral or bilateral puncture, but there are few reports on whether it is equally effective for the accompanying distant lumbosacral pain.
Objective: To analyze the clinical effect of unilateral or bilateral PVP on thoracolumbar OVCF with distant lumbosacral pain.
Methods: The clinical data of patients with single-stage OVCF treated with PVP in our hospital from March 2019 to March 2023 were retrospectively analyzed.
Comparative cardiovascular safety of romosozumab versus bisphosphonates in Japanese patients with osteoporosis: a new-user, active comparator design with instrumental variable analyses.
J Bone Miner Res
January 2025
Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima-city, Fukushima, Japan.
This study analyzed the association of romosozumab, a human monoclonal antibody with bone-forming and bone resorption-inhibiting effects, and bisphosphonates with the development of cardiovascular disease among patients with osteoporosis. A new-user design was employed to address selection bias, and instrumental variable analysis was used to address confounding by indication. Japanese patients aged ≥40 years, diagnosed with osteoporosis or experienced a fragility fracture, were admitted to medical facilities covered by a commercial administrative claims database, and newly prescribed romosozumab or bisphosphonates after the commercialization of romosozumab in Japan (March 4, 2019) were included based on verification of a 180-day washout period.
View Article and Find Full Text PDFOsteoporotic thoracolumbar spine fractures in the elderly: alterations in GNRI and BMP-2 in delayed union and associated factors.
Am J Transl Res
December 2024
Department of Orthopaedics, Liyang Hospital of Chinese Medicine Changzhou 213300, Jiangsu, China.
Objective: To investigate the alterations in the Geriatric Nutritional Risk Index (GNRI) and bone morphogenetic protein 2 (BMP-2) levels and identify associated factors in older adults with delayed union of osteoporotic thoracolumbar spine fractures.
Methods: From June 2021 to June 2023, 139 elderly patients with osteoporotic thoracolumbar spine fractures were selected and divided into a delayed group and a normal group according to the fracture healing status at 6 months postoperatively. GNRI and BMP-2 levels were assessed in both cohorts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!